ClinicalTrials.gg
CompletedNCT04318080TIRHOLUpdated Sep 24, 2025Results posted

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

A Phase 2 interventional study of Tislelizumab in Classical Hodgkin Lymphoma, sponsored by BeiGene. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.

Enrollment
315th of 818
46 · median 35
Started
2020
with 10 others
Phase 2
346 of 970
30 open now
Registered
866th of 970
by date

Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 315th largest by enrollment of the 818 interventional ones that give a count, is one of 11 that started in 2020, is one of 346 in phase 2, and was the 866th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 970 studies in Hodgkin Disease with a site in United States, or all of them as a file.
02

Study summary

This was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments. The main outcome was to assess overall response rate (ORR) across both cohorts. Participants continued receiving the study treatment until their disease got worse, side effects became too severe, or they chose to stop for other reasons.

03

Conditions studied

  • Classical Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants had a confirmed diagnosis of classical Hodgkin lymphoma (cHL).
  2. Participants had either:

    • Relapsed cHL, defined as disease progression after a partial response (PR) or complete response (CR) to their most recent therapy; or
    • Refractory cHL, defined as failure to achieve PR or CR to their most recent therapy.

    Participants were assigned to one of two cohorts based on the following:

    Cohort 1: Participants who were relapsed or refractory after prior hematopoietic stem cell transplantation (HSCT):

    1. Had failed to achieve a response or had experienced disease progression following autologous HSCT (a transplant using the participant's own stem cells).
    2. Were not considered candidates for additional autologous or allogeneic HSCT (a transplant using donor stem cells).

    Cohort 2: Participants who were relapsed or refractory to salvage chemotherapy and had not received prior HSCT:

    1. Were not considered candidates for autologous or allogeneic HSCT.
    2. Had received at least one prior systemic therapy regimen for cHL.
  3. Participants had , defined as at least one positron emission tomography (PET)-positive, 2-\[18F] fluoro-2-deoxy-D-glucose (FDG)-avid nodal lesion greater than 1.5 centimeters (cm) in longest diameter, or at least one FDG-avid extranodal lesion (hepatic nodule) greater than 1.0 cm in longest diameter.
  4. Participants had an (ECOG) performance status score of 0 or 1, indicating full activity or restricted activity but capable of self-care.

Key Exclusion Criteria:

  1. Participants had nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma.
  2. Participants had received prior allogeneic HSCT.
  3. Participants had received prior therapy targeting immune checkpoint pathways, including programmed cell death protein 1 (), programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  4. Participants had active disease or a history of autoimmune disease with potential to relapse.

Note: Additional inclusion and exclusion criteria defined in the protocol may have applied.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants who had relapsed or refractory classical Hodgkin lymphoma and had either not achieved a response or had disease progression following autologous hematopoietic stem cell transplantation received tislelizumab 200 milligrams (mg) intravenously every 3 weeks.

    Drug: Tislelizumab

  • Experimental
    Cohort 2

    Participants who had relapsed or refractory classical Hodgkin lymphoma and had either not achieved a response or had disease progression after at least one prior systemic therapy and were not candidates for autologous or allogeneic hematopoietic stem cell transplantation received tislelizumab 200 mg intravenously every 3 weeks.

    Drug: Tislelizumab

Interventions

  • 200 milligrams (mg) intravenously every 3 weeks (Q3W)

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) by Positron Emission Tomography (PET) and Computed Tomography (CT) per the Lugano Classification and as determined by the investigator. CR was defined as the complete disappearance of all target lesions on PET-CT, with no new lesions detected. PR was defined as a significant reduction in metabolic activity or lesion size consistent with partial tumor shrinkage as per Lugano criteria.

    Time frame: From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.

Secondary outcomes

  1. Complete Response Rate (CRR)

    CRR was defined as the percentage of participants who achieved a best overall response of complete response (CR) by PET-CT or CT per the Lugano Classification and determined by the investigator. CR was defined as the complete disappearance of all target lesions on PET-CT or CT, with no new lesions detected.

    Time frame: From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.

  2. Duration of Response (DOR)

    DOR was defined as the time from the date that response criteria (CR or PR) were first met to the date of objectively documented disease progression or death, whichever occurred first. Participants without an event were censored at the data cutoff or end of study, whichever occurred first. Participants who received new anti-lymphoma therapies, including Hematopoietic Stem Cell Transplantation (HSCT), before having an event were censored at the date of therapy initiation. Only participants with confirmed response were included in the analysis. Median DOR was estimated using the Kaplan-Meier method.

    Time frame: From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.

  3. Time to Response (TTR)

    TRR was defined as the time from the date of the first dose of tislelizumab to the date the response criteria were first met CR or PR per the Lugano Classification, and was analyzed only in participants who achieved an overall response; CR was defined as complete disappearance of disease, PR as ≥50% reduction in tumor burden, and Overall Response Rate (ORR) included participants with either CR or PR.

    Time frame: From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.

  4. Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Treatment-emergent adverse events (TEAEs) were defined as any AE that began or worsened in severity after the first dose of study treatment and up to 90 days following the last dose, regardless of initiation of new anti-lymphoma therapy. The following safety data are reported: Number of participants with any TEAEs: Participants who experienced at least one TEAE of any grade. Number of participants with any Grade ≥3 TEAEs: Participants who experienced at least one TEAE that was Grade 3 or higher in severity. Number of participants with any SAEs: Participants who experienced at least one serious adverse event, regardless of relationship to study treatment, occurring up to 90 days after the last dose.

    Time frame: From the date of the first dose of tislelizumab through 90 days after the last dose (maximum duration of tislelizumab exposure was 168 weeks)

07

Results

Posted Sep 24, 2025

Participant flow

This study was conducted at multiple centers across France, the United States, Belgium, and Australia from August 20, 2020, to August 29, 2024.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started1531
Treated1431
Completed00
Not completed1531
Withdrew: Study closed by sponsor1022
Withdrew: Death39
Withdrew: Withdrawal by subject10
Withdrew: Protocol deviation10

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) by Positron Emission Tomography (PET) and Computed Tomography (CT) per the Lugano Classification and as determined by the investigator. CR was defined as the complete disappearance of all target lesions on PET-CT, with no new lesions detected. PR was defined as a significant reduction in metabolic activity or lesion size consistent with partial tumor shrinkage as per Lugano criteria.

Time frame:
From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR)
Percentage of ParticipantsCohort 1Cohort 2Total
Overall Response Rate (ORR)64.3 (35.1 to 87.2)64.5 (45.4 to 80.8)64.4 (48.8 to 78.1)
Statistical analysis
  • Total · Binomial Exact Test · p = 0.0044 (One-sided p-value based on a binomial exact test comparing observed ORR to historical rate of 45%.) · Z-test: 2.62
SecondaryComplete Response Rate (CRR)

CRR was defined as the percentage of participants who achieved a best overall response of complete response (CR) by PET-CT or CT per the Lugano Classification and determined by the investigator. CR was defined as the complete disappearance of all target lesions on PET-CT or CT, with no new lesions detected.

Time frame:
From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.
Reported as:
Number · Percentage of Participants
Complete Response Rate (CRR)
Percentage of ParticipantsCohort 1Cohort 2Total
Complete Response Rate (CRR)42.9 (17.7 to 71.1)25.8 (11.9 to 44.6)31.1 (18.2 to 46.6)
SecondaryDuration of Response (DOR)

DOR was defined as the time from the date that response criteria (CR or PR) were first met to the date of objectively documented disease progression or death, whichever occurred first. Participants without an event were censored at the data cutoff or end of study, whichever occurred first. Participants who received new anti-lymphoma therapies, including Hematopoietic Stem Cell Transplantation (HSCT), before having an event were censored at the date of therapy initiation. Only participants with confirmed response were included in the analysis. Median DOR was estimated using the Kaplan-Meier method.

Time frame:
From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.
Reported as:
Median · months
Duration of Response (DOR)
monthsCohort 1Cohort 2Total
Duration of Response (DOR)12.25 (5.55 to 12.25)6.64 (2.79 to NA)12.25 (3.02 to NA)
SecondaryTime to Response (TTR)

TRR was defined as the time from the date of the first dose of tislelizumab to the date the response criteria were first met CR or PR per the Lugano Classification, and was analyzed only in participants who achieved an overall response; CR was defined as complete disappearance of disease, PR as ≥50% reduction in tumor burden, and Overall Response Rate (ORR) included participants with either CR or PR.

Time frame:
From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.
Reported as:
Median · months
Time to Response (TTR)
monthsCohort 1Cohort 2Total
Time to Response (TTR)2.69 (2.1 to 5.5)2.69 (0.3 to 5.6)2.69 (0.3 to 5.6)
SecondaryNumber of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Treatment-emergent adverse events (TEAEs) were defined as any AE that began or worsened in severity after the first dose of study treatment and up to 90 days following the last dose, regardless of initiation of new anti-lymphoma therapy. The following safety data are reported: Number of participants with any TEAEs: Participants who experienced at least one TEAE of any grade. Number of participants with any Grade ≥3 TEAEs: Participants who experienced at least one TEAE that was Grade 3 or higher in severity. Number of participants with any SAEs: Participants who experienced at least one serious adverse event, regardless of relationship to study treatment, occurring up to 90 days after the last dose.

Time frame:
From the date of the first dose of tislelizumab through 90 days after the last dose (maximum duration of tislelizumab exposure was 168 weeks)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1Cohort 2
Number of participants with any TEAEs1230
Number of participants with any TEAEs with grade >= 3412
Number of participants with any SAEs49

Adverse events

Collected over All-cause mortality was reported from randomization to 29 Aug 2024 (4 years). AEs were reported from first tislelizumab dose to 90 days post-last dose (max exposure: 168 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 13/14 (21.4%)4/14 (28.6%)12/14 (85.7%)
Cohort 29/31 (29%)9/31 (29%)30/31 (96.8%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventCohort 1Cohort 2
Blood creatine phosphokinase increasedInvestigations1/140/31
Lipase increasedInvestigations1/140/31
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/140/31
Cutaneous t-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/140/31
DyspnoeaRespiratory, thoracic and mediastinal disorders1/140/31
Coeliac diseaseGastrointestinal disorders0/141/31
Chest painGeneral disorders0/141/31
PyrexiaGeneral disorders0/141/31
PeritonitisInfections and infestations0/141/31
SepsisInfections and infestations0/141/31
Most frequent other events
Showing 10 of 137
Most frequent other events
EventCohort 1Cohort 2
AstheniaGeneral disorders1/149/31
Influenza like illnessGeneral disorders3/140/31
CoughRespiratory, thoracic and mediastinal disorders3/145/31
DyspnoeaRespiratory, thoracic and mediastinal disorders3/143/31
Dry skinSkin and subcutaneous tissue disorders3/142/31
NauseaGastrointestinal disorders1/145/31
DiarrhoeaGastrointestinal disorders2/142/31
VomitingGastrointestinal disorders2/143/31
FatigueGeneral disorders2/144/31
BronchitisInfections and infestations2/143/31

Baseline characteristics

The Safety Analysis Set included all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Total
Mean43.9 ± 15.7859.6 ± 21.9554.7 ± 21.37
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female41115
Male102030
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Total
White358
Not Reported112637
Patient Status at Time of Enrollment
Patient Status at Time of Enrollment(Participants)Cohort 1Cohort 2Total
Refractory01313
Relapse/Progression141832
The Eastern Cooperative Oncology Group (ECOG) Performance Status
The Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Cohort 1Cohort 2Total
0 (Normal activities)101828
1 (Ambulatory able to carry out work)41317
Number of prior lines of therapy for cHL
Number of prior lines of therapy for cHL(Participants)Cohort 1Cohort 2Total
1077
291726
34610
4112
08

Study locations

4 sites
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201-2013, United States
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920-1511, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112-5550, United States
  • Monash Health
    Clayton, Victoria VIC 3168, Australia
09

References and documents

Publications

  • Ghesquières H, López-Guillermo A, De la Cruz F, et al. Tislelizumab, an anti-PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter LYSA phase 2 study conducted in Western countries. Blood. 2023;142(Suppl 1):1717. DOI:10.1182/blood-2023-188545
  • Ghesquières H, et al. TIRHOL (BGB-A317-210): International Phase 2 Study in Relapsed/Refractory Classical Hodgkin Lymphoma. Presented at: Congrès de la Société Française d'Hématologie (SFH); March 2024; Paris, France.
  • Ghesquières H, López-Guillermo A, De la Cruz F, et al. Final analysis from the LYSA phase 2 TIRHOL study (BGB-A317-210): tislelizumab in relapsed/refractory classical Hodgkin lymphoma. Presented at: 18th International Conference on Malignant Lymphoma (ICML); June 18-22, 2025; Lugano, Switzerland. https://doi.org/10.1002/hon.70093_130

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Dec 2022, 27 months.

Results were first posted in Sep 2025, 2 years 9 months after primary completion. A results delay was requested in Dec 2023.

Of 206 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2020
First posted
Mar 23, 2020
StartActual
Aug 20, 2020
Primary completionActual
Dec 12, 2022
CompletionActual
Aug 29, 2024
Results delay requested
Dec 12, 2023
Results first posted
Sep 24, 2025
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04318080
Lead sponsor
BeiGene
Collaborators
Lymphoma Study Association
Responsible party
Sponsor
First posted
Mar 23, 2020
Start date
Aug 20, 2020
Primary completion
Dec 12, 2022
Completion
Aug 29, 2024
Results posted
Sep 24, 2025
Last update
Sep 24, 2025

Study contacts

Herve Ghesguieres
principal investigator · Lymphoma Study Association

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion